Početna › Multipli mijelom › Ohio
Kliničke studije za Multipli mijelom u državi Ohio
46 studija za Multipli mijelom traži sudionike na lokacijama u državi Ohio.
Gradovi u državi Ohio
Službeni tekst studije (engleski)
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 104, Columbus
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07582432A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Cincinnati
- Research Site, Cleveland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- The James Cancer Hospital and Solove Research Institute At Ohio State University, Columbus
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Gabrail Cancer Center, Canton
- The Christ Hospital, Cincinnati
- Dayton Physicians Network Urology, Dayton
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- University Hospitals Cleveland Medical Center, Cleveland
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06500884A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Cleveland Clinic, Cleveland
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07149857Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology, Columbus
U tijeku regrutacijaFaza 2
Od 60 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06052826A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Ohio State University, Columbus
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07393282A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
- i još 4
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05552222TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Cincinnati Medical Center, Cincinnati
- Kettering Health, Kettering
- West Chester Hospital, West Chester
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT02693535Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06465316Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
U tijeku regrutacijaOpažajna studija
2 Months · Oba spola · Ažurirano 16. ruj 2026. · NCT00900198A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Cleveland Clinic, Cleveland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Oncology Hematology Care, Cincinnati
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06297226Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- TriHealth Cancer and Blood Institute, Cincinnati
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT07555938A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Cleveland
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 27. kol 2026. · NCT07681596MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- i još 5
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT06152575Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
- Gabrail Cancer & Research Center, Canton
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT06087653A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Canton
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT05714839Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OhioHealth O'Bleness Hospital, Athens
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- i još 15
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04566328A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Ohio State University, Columbus
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT06292780A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT05651932Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Cincinnati
- Research Site, Cleveland
- Research Site, Columbus
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. kol 2026. · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 12. kol 2026. · NCT07280013A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
- The Ohio State University /ID# 271336, Columbus
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 21. srp 2026. · NCT06892522A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT05650632Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 8. srp 2026. · NCT07657312A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- The Ohio State University James Cancer Hospital, Columbus
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. srp 2026. · NCT05137054Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Indu and Raj Soin Medical Center, Beavercreek
- Saint Elizabeth Boardman Hospital, Boardman
- Dayton Physicians LLC-Miami Valley South, Centerville
- i još 17
U tijeku regrutacijaFaza 3
Sve dobne skupine · Oba spola · Ažurirano 10. lip 2026. · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Cincinnati, Cincinnati
- Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
- Ohio State Medical Center, James Cancer Center, Columbus
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. lip 2026. · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- The Ohio State University- The James Cancer Hospital and Solove Research Institute, Columbus
U tijeku regrutacijaFaza 2
Od 19 godina i više · Oba spola · Ažurirano 4. lip 2026. · NCT06974786Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- The Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lip 2026. · NCT05145400A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 27. svi 2026. · NCT07609030Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
U tijeku regrutacijaFaza 1
Od 13 godina i više · Oba spola · Ažurirano 5. svi 2026. · NCT04771572A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Columbus
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. tra 2026. · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Oncology Hematology Care, Cincinnati
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 22. tra 2026. · NCT05972135Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Ohio State University James Cancer Hospital, Columbus
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 20. tra 2026. · NCT03761108A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- The Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 24. ožu 2026. · NCT04988555Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.